Home・Lista de Ações・AtriCure Inc

AtriCure Inc

Abrir

SetorSaúde

39.02 1.51

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

38.35

Máximo

39.19

Indicadores-chave
By Trading Economics
Rendimento	8.8M 9M
Vendas	12M 154M
P/E Médio do Setor	177.952 64.641
EPS	0.18
Margem de lucro	5.83
Funcionários	1,350
EBITDA	-3.8M 3.2M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+22.13% upside

Dividendos
By Acuity
Próximos Ganhos	28 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	132M 1.9B
Abertura anterior	37.51
Fecho anterior	39.02

Sentimento de Notícias

By Acuity

34%

66%

104 / 340 Ranking em Healthcare

AtriCure Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 20:06 UTC

AtriCure Inc. shares are higher during Monday's session, regaining ground after an earlier pullback. Broader market trends support positive investor sentiment.

31 de jul. de 2026, 20:03 UTC

News

AtriCure shares are lower amid significant insider selling, including a $233,280 sale by Chief Scientific Officer Vinayak Doraiswamy and options exercised by Board Member Sven Wehrwein.

30 de jul. de 2026, 18:56 UTC

AtriCure Inc's shares are lower today, impacted by declines in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

29 de jul. de 2026, 20:03 UTC

News

AtriCure Inc shares reached a 52-week high of $43.18 following better-than-expected quarterly earnings, despite a pullback earlier in the session.

28 de jul. de 2026, 19:21 UTC

AtriCure Inc's shares are higher today amid stronger gains in U.S. and European indices, with no specific company news identified for the movement.

27 de jul. de 2026, 20:02 UTC

News

AtriCure Inc shares are higher as the company prepares for two investor conferences and highlights CEO Michael Carrel's leadership appointment.

24 de jul. de 2026, 21:41 UTC

AtriCure Inc. shares traded roughly flat in after-market hours. The stock has performed well recently, positioned near the upper end of its monthly range.

23 de jul. de 2026, 21:51 UTC

News

AtriCure reported strong Q2 results and raised EPS guidance but shares fell in after-market trading, marking the sixth consecutive session of declines.

22 de jul. de 2026, 19:56 UTC

AtriCure Inc shares are trading lower, reaching a session low just before 15:30 ET, despite remaining above the 20-day moving average.

21 de jul. de 2026, 19:16 UTC

AtriCure Inc shares are trading lower today, continuing a trend of declines over the past three sessions, despite gains in the Nasdaq 100 Index.

20 de jul. de 2026, 19:51 UTC

AtriCure Inc continues higher today, maintaining strength since Friday's close, despite a recent pullback earlier in the session.

Comparação entre Pares

Variação de preço

AtriCure Inc Previsão

Preço-alvo

By TipRanks

22.13% parte superior

Previsão para 12 meses

Média 47.29 USD 22.13%

Máximo 55 USD

Mínimo 36 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para AtriCure Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para AtriCure Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

104 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.